Antitumor effects of human recombinant macrophage colony-stimulating factor against @entity35 XXXX .

@entity1313 @entity5 @entity11 @entity1975 @entity23142 @entity35
The tumoricidal effects of @entity23142 were examined using two subcutaneously-transplanted @entity35 @entity1313 cell lines, 9L and T9 @entity11 . In @entity35 treated with high-dose @entity23142 (16 million U/kg administered for 4 days a week for 3 weeks), 9L @entity11 growth was inhibited by 81.9% following subcutaneous (s.c.) injection and by 70.5% after intraperitoneal (i.p.) injection and T9 @entity11 growth was inhibited by 69.2% after i.p. injection. After short-term treatment with high-dose @entity23142 (32 million U/kg administered s.c. for 6 consecutive days, 9L @entity11 growth was inhibited by 82.1%. All these inhibitory effects differed significantly compared with the respective untreated control groups. However, treatment with low-dose @entity23142 (1.6 million U/kg administered s.c. for 4 days a week for 3 weeks) showed no significant effects against 9L and T9 @entity11 growth compared with the untreated controls. No significant effects of @entity23142 against cell proliferation, measured as @entity1975 expression, were observed in any group. Significant hematopoietic effects on the leukocyte counts were observed only in the groups treated with high dose @entity23142 . These results suggest that @entity23142 at a high dose which produces hematopoietic effects on peripheral leukocytes inhibits the growth of @entity11 . This inhibitory effect may have been due to a tumoricidal mechanism of @entity23142 that depended on the production or release of some hematopoietic soluble factors, but was independent of @entity1975 expression by the @entity5 .
